Physician profile
Sean Patrick Considine
NPI 1861029068
$2,083.01
in general payments reported to CMS, 2019-2025
17 companies · $1,341 in 2025
The $1,341 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $742 · 2025: $1,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,985 · Education: $97.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,985.02 |
| Education | $97.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $380.07 | 2024-2025 | Hydrus Microstent, Rocklatan, Eysuvis |
| Mallinckrodt Hospital Products INC. | $309.07 | 2024-2025 | Acthar |
| Abbvie INC. | $254.63 | 2024-2025 | |
| Biotissue Holdings INC. | $223.75 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $170.96 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $156.27 | 2024-2025 | Vyzulta, Miebo, Infuse |
| Harrow Eye, LLC | $143.73 | 2024-2025 | Vevye, Ilevro |
| Sight Sciences, INC. | $108.00 | 2024 | Omni Surgical System |
| Merz Pharmaceuticals, LLC | $100.12 | 2024-2025 | Xeomin |
| Dompe US, INC. | $60.60 | 2025 | Oxervate |
| Rxsight INC | $43.23 | 2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Glaukos Corporation | $34.55 | 2025 | Idosetr |
| Topcon Healthcare, INC. | $29.56 | 2025 | |
| Sun Pharmaceutical Industries INC. | $20.77 | 2024 | |
| Oyster Point Pharma, INC. | $17.61 | 2024 | Tyrvaya |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $16.24 | 2024 | Purified Cortrophin Gel |
| Oasis Medical, INC. | $13.85 | 2025 | Oasis Tears |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Considine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.